The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the ...

According to the bulletin, out of the 150 reservoirs, 20 are dedicated to hydroelectric projects, with a total live storage capacity of 35.30 billion cubic meters (BCM). The CWC bulletin on July 4 ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene ... coats in ...

Baird analyst Joe Vruwink raised the firm’s price target on PTC (PTC) to $228 from $226 and keeps an Outperform rating on the shares. The firm said management was very forceful that disruption ...

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago. These figures ...

Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Healthcare, Technology and Consumer Services sectors led shares lower. At the close in NYSE,... Investing.com ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $106.7 million in its third quarter. The Warren, New Jersey-based company said it had a loss ...

PTC Industries stock surged 278% in two years, boosted by strong financials and significant orders, including one from Israel ...